Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 2,013,511 shares, an increase of 111.7% from the August 15th total of 951,173 shares. Currently, 3.0% of the company’s stock are sold short. Based on an average trading volume of 2,642,330 shares, the days-to-cover ratio is presently 0.8 days.

In other Immune Pharmaceuticals news, CMO Monica E. Luchi bought 777,778 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were acquired at an average cost of $0.45 per share, with a total value of $350,000.10. Following the completion of the transaction, the chief marketing officer now owns 777,778 shares in the company, valued at $350,000.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Kazado bought 666,667 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $300,000.15. Following the completion of the transaction, the director now owns 907,290 shares of the company’s stock, valued at approximately $408,280.50. The disclosure for this purchase can be found here. Insiders own 17.83% of the company’s stock.

Separately, FBR & Co reaffirmed a “buy” rating on shares of Immune Pharmaceuticals in a research report on Wednesday, June 22nd.

Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 0.29 on Wednesday. The company’s market capitalization is $22.96 million. Immune Pharmaceuticals has a one year low of $0.20 and a one year high of $1.57. The company has a 50-day moving average price of $0.36 and a 200 day moving average price of $0.40.

Immune Pharmaceuticals (NASDAQ:IMNP) last issued its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). On average, analysts forecast that Immune Pharmaceuticals will post ($0.56) EPS for the current fiscal year.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

5 Day Chart for NASDAQ:IMNP

Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.